Abstract:Background: Description of immune landscapes that indulge or restrain survival and proliferation of malignant cells is critical to the improvement of therapeutic strategies. Acute myeloid leukemia (AML) remains a severe life-threatening malignancy and often confronts treatment dilemma in clinic. Although γδ T cells exhibit independent and potent cytotoxicity against leukemic cells in vitro and in the mouse models, efficacy of γδ T cell-based immunotherapy on AML patients has seemed unsatisfying so far. How the anti-AML capacity of γδ T cells is suppressed in vivo is unknown. Aims: In this study, we aim to dissect the abnormal changes and functions of intrinsic γδ T cells in the context of AML and dig out the correlated factors in the AML tumor environment. Methods: 1. Immunophenotyping analyses of γδ T cells in bone marrows from newly diagnosed AML patients (n = 62) were detected using flow cytometry, compared with healthy donors (n=51). The levels of TGF-β family members in the supernatants of bone marrows were detected by ELISA kits. 2. Peripheral blood mononuclear cells (PBMCs) isolated from healthy donors were stimulated with AML blasts and morphogenetic protein 2 (BMP2) to validate clinical phenotypes. Functional experiments were performed to depict the role of a BMP2-induced subset of γδ T cells in the anti-AML activity of effector γδ T cells. 3. To confirm the findings described above, we established human CD34+ cells-implanted mice models followed by injection with luciferase and GFP co-expressing AML cells. Results: The proportions of total γδ T cells and Vδ1+ fraction were not significantly different between AML patients and donors. In contrast, the percentage of Vδ2+ T cells was markedly decreased in AML patients. Meanwhile, a key activating receptor of γδ T cells, NKG2D, was dramatically decreased and regulatory receptors CD25 and PD-1 were increased on Vδ2+ T cells in AML patients. The expansion capacity of Vδ2+ T cells was profoundly impaired in AML patients. The functional impairments of γδ T cells were accompanied with an abnormally increased levels of BMP2, rather than TGF-β, BMP4 and ActivinA, in AML patients. Furthermore, we demonstrated that BMP2 directly induced an aberrant γδ T cells subset expressing Vδ2+CD25+CD127low (abbreviated as BMP2-Vδ2) in PBMCs from healthy donors. Consistently, BMP2-Vδ2 cells were significantly increased in the bone marrows of AML patients compared with donors. The frequencies of BMP2-Vδ2 cells correlated to soluble BMP2 levels and the disease status. Distinct from effector Vδ2 cells, BMP2-Vδ2 not only lost the ability of killing AML cells, but also was able to reduce the anti-AML activity of effector Vδ2 cells after co-cultures. In AML-loaded humanized mice, treatment with BMP2 induced the occurrence of BMP2-Vδ2 cells and reduced the survival rate of mice. Injection of BMP2-Vδ2 cells significantly attenuated the activity of effector Vδ2 cells on the elimination of AML cells in mice. Together, these results demonstrated the immunoregulatory effect of BMP2 on the phenotype and function of γδ T cells in AML microenvironment. Summary/Conclusion: We first reported that dysregulated BMP2 in AML triggered an immunosuppressive subset of γδ T cells, leading to the impairment of anti-AML function of effector γδ T cells. Our findings provide a novel insight into the mechanisms of immunosuppression in the context of leukemia and suggest potential targets for the treatment of AML and other hematopoietic malignancies.

BMP4 Moderates Glycolysis and Regulates Activation and Interferon-Gamma Production in CD4+ T Cells

BMP4 Promotes Hepatocellular Carcinoma Proliferation by Autophagy Activation Through JNK1-mediated Bcl-2 Phosphorylation

Tumor and Stem Cell Biology BMP 4 Administration Induces Differentiation of CD 133 þ Hepatic Cancer Stem Cells , Blocking Their Contributions to Hepatocellular Carcinoma

Bone Morphogenetic Protein 4 Inhibits Liposaccharide-Induced Inflammation in the Airway.

Bmp4 Acts Upstream Of Fgf In Modulating Thymic Stroma And Regulating Thymopoiesis

Data from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

BMP4 Facilitates Beige Fat Biogenesis Via Regulating Adipose Tissue Macrophages.

BMP4 Mediates the Interplay Between Adipogenesis and Angiogenesis During Expansion of Subcutaneous White Adipose Tissue

Bmp4 Enhances Hepatocellular Carcinoma Proliferation by Promoting Cell Cycle Progression Via Id2/Cdkn1b Signaling

Bone morphogenetic protein 4 ameliorates bleomycin-induced pulmonary fibrosis in mice by repressing NLRP3 inflammasome activation and epithelial-mesenchymal transition

Bone Morphogenetic Proteins Inhibit CD40L- and IL-21-Induced Ig Production In Human B Cells: Differential Effects of BMP-6 and BMP-7

Role of Bone Morphogenetic Protein 4 in the Differentiation of Brown Fat-Like Adipocytes.

BMP—4 Induced Proliferation and Oriented Differentiation of Rat Hepatic Oval Cells into Hepatocytes

Bone morphogenetic protein 4 alleviates pulmonary fibrosis by regulating macrophages

Synergistic Effect of Tgf-Beta Superfamily Members on the Induction of Foxp3(+) Treg

BMP4-mediated brown fat-like changes in white adipose tissue alter glucose and energy homeostasis

BMP4-mediated browning of perivascular adipose tissue governs an anti-inflammatory program and prevents atherosclerosis

BMP8B Activates Both SMAD2/3 and NF-κB Signals to Inhibit the Differentiation of 3T3-L1 Preadipocytes into Mature Adipocytes

Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression.

S124: BONE MORPHOGENETIC PROTEIN 2 TRIGGERS OFF AN IMMUNOSUPPRESSIVE EFFECT OF ΓΔ T CELLS IN ACUTE MYELOID LEUKEMIA

Bone morphogenetic protein 4 inhibits pulmonary fibrosis by modulating cellular senescence and mitophagy in lung fibroblasts